Saturday, January 23, 2010
GlaxoSmithKline opening up malaria data a wee bit, but more needed
Robert Langreth in an article at Forbes.Com on January 20 (GlaxoSmithkline's Malaria Plan: Limit Profits, Open Labs) reports that Glaxo Smith Kline is becoming a bit more open with their data on malaria drug/vaccine development. Apparently, they plan to open up their labs and some of their data to non profit collaborators such as Emory University. Sounds like this could be a good first step. But if they really want to advance malaria vaccine research, perhaps they should release their data to everyone? I get that they want/need to make a profit, but if they want to try and get credit for being open, I think they really should jump into the deep end and do something radical. Just sharing bits and pieces of data with a few labs is not a particularly stunning move.
Subscribe to: Post Comments (Atom)
Most recent post
Panoramas from the past ...
In 1997, my then girlfriend (now wife) and I went camping in Death Valley. It was our fourth trip there to camp in grad. school. I brought m...
Just got this press release by email. I am sick of receiving dozens of unsolicited press releases, especially those in topics not related ...
New article out from the Eisen Lab: Isolation and sequence-based characterization of a koala symbiont: Lonepinella koalarumSee Isolation and sequence-based characterization of a koala symbiont: Lonepinella koalarum Paper based on PhD thesis work of Katie Dahlha...
I have a new friend in Google Scholar Updates I have written about the Updates system before and if you want more information please see...
I think this is closer to what you'd like to see happen:ReplyDelete
In case the link gets mangled, the basic idea is that GSK will be making a public release of the results of their huge Plasmodium screen, showing us the identities (with structures) of the 13,500 compounds that were found to kill the parasite.
Just found their press release which says more about the openness:ReplyDelete
"13,500 malaria compounds to be made freely available
GSK has screened its pharmaceutical compound library of more than 2 million molecules for any that
may inhibit the malaria parasite P.falciparum, the deadliest form of malaria, which is found primarily in
sub-Saharan Africa. This exercise took five scientists a year to complete, and has yielded more than
13,500 compounds that could lead to the development of new and innovative treatments for malaria,
which kills at least one million children every year in Africa.
GSK will make these findings, including the chemical structures and associated assay data, freely
available to the public via leading scientific websites. The release of these data will mark the first time
that a pharmaceutical company has made public the structures of so many of its compounds in the
hope that they could lead to new medicines for malaria."
Though unclear exactly when where stuff will be released. Much of the rest of the press release focuses on collaborative projects where data will be open to the collaborators but not to all. So - good first step. Better than I imagined. But still not fully open ...